IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
Aggregated presentation by day and by market
IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
- 26 September 2023 - 1 mins read
Aggregated presentation by day and by market
Related Press Releases
![TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
19 January 2024
7 mins read
TOXINS 2024: Results from Ipsen’s AboLiSh study demonstrate the significant clinical benefit of using injection guidance techniques when treating spasticity with abobotulinumtoxinA
![IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
14 November 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
![Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
13 November 2023
11 mins read
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...
![IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
07 November 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
![Ipsen updates on QM-1114 regulatory process Ipsen updates on QM-1114 regulatory process](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
03 October 2023
5 mins read
Ipsen updates on QM-1114 regulatory process
![Ipsen nominates Pascal Touchon to its Board of Directors as new independent director Ipsen nominates Pascal Touchon to its Board of Directors as new independent director](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
04 September 2023
5 mins read
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
![Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
21 August 2023
15 mins read
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
![IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023 IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
18 July 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023
![Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
01 June 2023
2 mins read
Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023
![Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U. Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
26 May 2023
7 mins read